EDIT
Editas Medicine, Inc.
$3.11
+2.64%
2026-05-08
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Key Fundamentals
Forward P/E
-3.35
EPS (TTM)
$-1.14
ROE
-326.1%
Revenue Growth (YoY)
-39.2%
Profit Margin
-281.6%
Debt/Equity
392.40
Price/Book
68.22
Beta
2.14
Market Cap
$300.6M
Avg Volume (10D)
1.3M
Recent Breakout Signals
No recent breakout signals detected for EDIT.
Recent Price Range (60 Days)
60D High
$3.64
60D Low
$1.67
Avg Volume
1.6M
Latest Close
$3.11
Get breakout alerts for EDIT
Sign up for Breakout Scanner to receive daily notifications when EDIT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Editas Medicine, Inc. (EDIT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors EDIT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. EDIT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.